AGP Executive Report
Last update: 10 hours agoNew Cancer Treatment in Europe: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD for adults and adolescents (12+) with previously untreated advanced classical Hodgkin lymphoma, marking the first immunotherapy-based regimen for newly diagnosed advanced cases in the EU. CLL Therapy Update: AbbVie received an expanded EU label for VENCLYXTO (venetoclax), adding fixed-duration combinations with acalabrutinib (with/without obinutuzumab) and with ibrutinib for previously untreated chronic lymphocytic leukemia—covering EU plus Iceland, Norway, and Liechtenstein. Transplant Milestone: Hansa Biopharma reported strong one-year outcomes for Idefirix (imlifidase) in highly sensitised patients after HLA-incompatible kidney transplants, with 90% graft failure-free survival at one year and 98% patient survival. Heat & Health Risk: A deadly spring heat wave across Europe shattered temperature records and has already been linked to multiple deaths, underscoring urgent heat-safety needs. Pet Health Tech in the Region: Fi expanded AI-powered GPS pet wearables to 38 countries, including Switzerland, Norway, and Liechtenstein, offering owners health insights and tracking while traveling.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
